TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

Rethink dosing and
administration

Just 1 subcutaneous self-injection every 2 weeks1

1

MINUTE
TO SELF-INJECT
for the majority
of patients1*

Clock icon

EVERY 2 WEEKS1

Calendar icon

3

CHOICE
FOR INJECTION
Abdomen, either
thigh, or either arm1

Image of a silhouette with injection sites highlighted - TAKHZYRO® (lanadelumab‐flyo) can be injected in different sites.

TAKHZYRO requires no reconstitution.1

The recommended starting dose is 300 mg every 2 weeks. TAKHZYRO every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1

As recommended in the established HAE Treatment Guidelines, remind patients to always have acute treatment on hand.2 Patients taking TAKHZYRO should also be encouraged to periodically check the date of their acute treatment to see if it has expired.

*In clinical trials, the majority of patients self-administered TAKHZYRO within 10 to 60 seconds.

Dosing and administration at a glance

TAKHZYRO1
C1-INHIBITOR PREVENTIVE THERAPIES3,4
Dosing frequency
Once every 2 weeks (starting dose)
Once every 3 to 4 days
Volume
2 mL
4 to 25 mL
Half-life
~2 weeks
56 to 69 hours
Manufacturing
Non-plasma derived, recombinant mAb
Derived from human plasma
Administration
Subcutaneous injection
Subcutaneous or intravenous injection/infusion
How supplied
Ready-to-use single dose
Reconstitution required

Table does not imply superiority in any respect, and does not include all products in the therapeutic class.

Please see full Prescribing Information for detailed dosage and administration information.

Based on calculations from approved product Prescribing Information and patient weight assumptions.

Lexi, a real TAKHZYRO® patient, and her mother, Heather looking at a photo album
Lexi
Heather

Support patients with information on self-administration

TAKHZYRO is intended for self-administration or administration by a caregiver after being trained by a healthcare professional.1 In clinical studies, the majority of patients self-administered TAKHZYRO within 10 to 60 seconds.1 You can use the FDA-approved Instructions For Use information below to show patients the proper way to administer TAKHZYRO. And let patients know they can refer to supplementary injection training materials to reinforce your instructions:

FDA-approved Instructions For Use

Injection Training Materials overview

Instructions For Use video

Cell phone icon

Keep patients on track

Even if your patients experience fewer or no attacks during treatment, talk to them about the importance of taking their medication as prescribed to help prevent future attacks.1

To support your efforts, patients can set up dosing reminders through the TAKHZYRO Text Reminder Program which will deliver reminders straight to their mobile phone whenever it's time to take TAKHZYRO.

Patients can sign up here

In addition to the text reminder program, consider encouraging patients to keep a journal tracking their experiences with HAE. They can record questions for upcoming appointments and note potential triggers, and the date, severity and location of any swelling episodes. This will help you identify patterns over time and inform adjustments to your patient’s treatment plan.

Timing is dependent upon when the forms are received by OnePath®. The Quick Start Program is available to all commercially insured patients ≥12 years of age who are US residents with a confirmed diagnosis of HAE. Takeda and its affiliates reserve the right to change or discontinue this program at any time, without notice. Void where prohibited by law. This program does not constitute a financial assistance program.

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-800-FDA-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-800-FDA-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

References: 1. TAKHZYRO (lanadelumab-flyo) [prescribing information]. Lexington, MA: Dyax Corp 2018. 2. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema–the 2017 revision and update. Allergy. 2018;73(8):1575-1596. 3. CINRYZE (C1 esterase inhibitor [human]) [prescribing information]. Lexington, MA: Shire ViroPharma Incorporated; 2018. 4. HAEGARDA [prescribing information]. Kankakee, IL: CSL Behring LLC; 2017.